NASDAQ | ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | Healthcare | Drug Manufacturers - General | 17.07% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 15.83% |
| VKTX | Viking Therapeutics Inc | Healthcare | Biotechnology | 5.61% |
| ZEAL | Zealand Pharma A/S | Healthcare | Biotechnology | 5.36% |
| ROG | Roche Holding AG | Healthcare | Drug Manufacturers - General | 5.13% |
| GPCR | Structure Therapeutics Inc. American Depositary Shares | Healthcare | Biotechnology | 4.81% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 4.63% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 3.66% |
| MTSR | Metsera, Inc. Common Stock | Healthcare | Biotechnology | 3.65% |
| 1801 | Innovent Biologics Inc | Healthcare | Biotechnology | 3.64% |
| AZN | AstraZeneca PLC ADR | Healthcare | Drug Manufacturers - General | 3.54% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.40% |
| TERN | Terns Pharmaceuticals Inc | Healthcare | Biotechnology | 2.79% |
| SRRK | Scholar Rock Holding Corp | Healthcare | Biotechnology | 2.70% |
| 128940 | Hanmi Pharm Co Ltd | Healthcare | Drug Manufacturers - Specialty & Generic | 2.70% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 2.63% |
| TAK | Takeda Pharmaceutical Co Ltd ADR | Healthcare | Drug Manufacturers - Specialty & Generic | 2.59% |
| GUBRA | Gubra A/S | Healthcare | Biotechnology | 2.40% |
| VGG1110E1079 | BIOHAVEN LTD | 2.09% | ||
| CORT | Corcept Therapeutics Incorporated | Healthcare | Biotechnology | 2.04% |